A Study of Acalabrutinib in Combination with Rituximab + (Bendamustine or Venetoclax) in Subjects with MCL

Trial Identifier: ACE-LY-106
Sponsor: AcertaPharma
Collaborator:
AstraZeneca
Start Date: April 2016
Primary Completion Date: June 2022
Study Completion Date: August 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Italian Translation
Polish Translation

Trial Locations

Country Location
IT Bologna, IT, 40138
PL Krakow, PL, 30-510
PL Lodz, PL, 93-510
PL Olsztyn, PL, 10-228
PL Warszawa, PL, 02-106
US, KY Louisville, KY, US, 40207
US, MI Ann Arbor, MI, US, 48109
US, New York Lake Success, New York, US, 11042
US, NJ Hackensack, NJ, US, 07601
US, NJ Morristown, NJ, US, 07960
US, OH Columbus, OH, US, 43210
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030
US, WA Seattle, WA, US, 98109
US, WA Seattle, WA, US, 98122